WASHINGTON, D.C. — Just now, the Senate HELP Committee advanced two bipartisan bills, all supported by P4ADNow, that will help to increase competition and lower prescription drug prices.

In response, P4ADNow CEO Merith Basey released the following statement: 

“We applaud the Senate HELP Committee for standing with patients and cracking down on tactics deployed by the pharmaceutical industry that block cheaper biosimilars and generics from coming to market. At a time when nine in ten Americans are demanding Congress do more to lower prescription drug prices, there is both an urgent need and an opportunity to pass these bills as soon as possible. Patients cannot wait.”

P4ADNow has been in support of both these bills for years and our community has pushed hard to get them to this point — including sending nearly 1,500 letters to lawmakers on the Senate HELP Committee in the past four days alone. We see a real path forward for these bills to pass in a number of potential packages later this year. 

The Ensuring Timely Access to Generics Act of 2025 (S. 3014), which targets sham citizen petitions that block generic entry, was amended and did not receive a vote today. This is another P4ADNow-supported bill, and we anticipate it will be included in a forthcoming July markup. 

###

Patients For Affordable Drugs Now is the only national, patient advocacy organization focused exclusively on policies to lower drug prices. We empower and mobilize patients and allies, hold accountable those in power, and fight to shape and achieve system-changing policies that make prescription drugs affordable for all people in the United States. P4ADNow is bipartisan and does not accept funding from organizations that profit from the development or distribution of prescription drugs. To learn more, visit: PatientsForAffordableDrugsNOW.org